Effectiveness of Hip Protectors to Reduce Risk for Hip Fracture from Falls in Long-Term Care.


Journal

Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243

Informations de publication

Date de publication:
11 2019
Historique:
received: 19 01 2019
revised: 22 06 2019
accepted: 02 07 2019
pubmed: 4 9 2019
medline: 5 3 2021
entrez: 4 9 2019
Statut: ppublish

Résumé

To generate evidence of the effectiveness of hip protectors to minimize risk of hip fracture at the time of falling among residents of long-term care (LTC) by contrasting rates of hip fractures between falls with and without hip protectors. A 12-month, retrospective cohort study. We retrospectively reviewed fall incident reports recorded during the 12 months prior to baseline in participating homes. A population-based sample comprising all residents from 14 LTC homes owned and operated by a single regional health authority, who experienced at least 1 recorded fall during the 12-month study. At baseline, the pooled mean (standard deviation) age of residents in participating homes was 82.7 (11.3) years and 68% were female. Hip protectors were worn in 2108 of 3520 (60%) recorded falls. Propensity to wear hip protectors was associated with male sex, cognitive impairment, wandering behavior, cardiac dysrhythmia, use of a cane or walker, use of anti-anxiety medication, and presence of urinary and bowel incontinence. The incidence of hip fracture was 0.33 per 100 falls in falls with hip protectors compared with 0.92 per 100 falls in falls without hip protectors, representing an unadjusted relative risk (RR) of hip fracture of 0.36 (95% confidence interval 0.14-0.90, P = .029) between protected and unprotected falls. After adjusting for propensity to wear hip protectors, the RR of hip fracture was 0.38 (95% confidence interval 0.14-0.99, P = .048) during protected vs unprotected falls. Hip protectors were worn in 60% of falls, and the risk of hip fracture was reduced by nearly 3-fold by wearing a hip protector at the time of falling. Given that most clinical trials have failed to attain a similar level of adherence, our findings support the need for future research on the benefits of dissemination and implementation strategies to maximize adherence with hip protectors in LTC.

Identifiants

pubmed: 31477556
pii: S1525-8610(19)30562-6
doi: 10.1016/j.jamda.2019.07.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1397-1403.e1

Informations de copyright

Copyright © 2019 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Alexandra M B Korall (AMB)

Simon Fraser University, Burnaby, British Columbia, Canada; Center for Hip Health and Mobility, Vancouver, British Columbia, Canada. Electronic address: Alexandra.Korall@umanitoba.ca.

Fabio Feldman (F)

Simon Fraser University, Burnaby, British Columbia, Canada; Center for Hip Health and Mobility, Vancouver, British Columbia, Canada; Fraser Health Authority, Surrey, British Columbia, Canada.

Yijian Yang (Y)

Simon Fraser University, Burnaby, British Columbia, Canada; Center for Hip Health and Mobility, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada.

Ian D Cameron (ID)

Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia.

Pet-Ming Leung (PM)

Fraser Health Authority, Surrey, British Columbia, Canada.

Joanie Sims-Gould (J)

Center for Hip Health and Mobility, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada.

Stephen N Robinovitch (SN)

Simon Fraser University, Burnaby, British Columbia, Canada; Center for Hip Health and Mobility, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH